Interleukin 33 Promotes Liver Sinusoidal Endothelial Cell Dysfunction and Hepatic Fibrosis in Diabetic Mice
Open Access
- 1 November 2025
- journal article
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 49 (6) , 1204-1218
Abstract
Background: Interleukin 33 (IL33) drives liver fibrosis, and individuals with type 2 diabetes mellitus are more likely advanced to liver fibrosis. However, the role of IL33 in diabetic liver fibrosis remains unclear, prompting our investigation.Methods: We developed a diabetes model in wild-type, IL33−/−, and suppression of tumorigenicity 2 (ST2−/−, IL33 receptor) mice. Furthermore, wild-type diabetic mice were injected with IL33 neutralizing antibody (αIL33). We also co-cultured human liver endothelial cells and human hepatic stellate cells to identify the role of IL33 in high palmitic acid and high glucose conditions.Results: Hepatic collagen deposition was increased in diabetic mice, which was alleviated by IL33 knockout, ST2 knockout, or administration of αIL33. Also, αIL33 treatment blunted liver sinusoidal endothelial cell (LSEC) dysfunction and inflammation during diabetic liver fibrosis progression. Recombinant IL33 (rIL33) treatment aggravated autophagy disruption in the presence of palm acid and high glucose in LSECs, which was blunted by autophagy agonist rapamycin administration and ERK/MAPK inhibitor PD98059 treatment. Hepatic stellate cell line LX-2 co-cultured with rIL33-pretreated LSECs displayed augmented activation, which was also attenuated by rapamycin or PD98059 pretreated.Conclusion: IL33 drives LSEC dysfunction and promotes diabetic hepatic fibrosis, thus a potential therapeutic target for diabetic liver fibrosis.Keywords
Funding Information
- Applied Basic Frontier Special Project of Wuhan Science and Technology Bureau (2020020601012246)
- National Natural Science Foundation of China (81602858)
This publication has 50 references indexed in Scilit:
- TJ-M2010-5, A self-developed MyD88 inhibitor, attenuates liver fibrosis by inhibiting the NF-κB pathwayChemico-Biological Interactions, 2022
- Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver diseaseObesity, 2021
- Adipocyte Fatty Acid Binding Protein Promotes the Onset and Progression of Liver Fibrosis via Mediating the Crosstalk between Liver Sinusoidal Endothelial Cells and Hepatic Stellate CellsAdvanced Science, 2021
- IL-33 in obesity: where do we go from here?Inflammation Research, 2019
- Erythrocytes From Patients With Type 2 Diabetes Induce Endothelial Dysfunction Via Arginase IJACC, 2018
- IL-33 Initiates Vascular Remodelling in Hypoxic Pulmonary Hypertension by up-Regulating HIF-1α and VEGF Expression in Vascular Endothelial CellsEBioMedicine, 2018
- IL-33 Exerts Neuroprotective Effect in Mice Intracerebral Hemorrhage Model Through Suppressing Inflammation/Apoptotic/Autophagic PathwayMolecular Neurobiology, 2016
- Metallothionein plays a prominent role in the prevention of diabetic nephropathy by sulforaphane via up-regulation of Nrf2Free Radical Biology and Medicine, 2015
- Interleukin-33-Dependent Innate Lymphoid Cells Mediate Hepatic FibrosisImmunity, 2013
- Paracrine Signals From Liver Sinusoidal Endothelium Regulate Hepatitis C Virus ReplicationHepatology, 2013